Bleeding Risk Estimation and the New BARC Definition of Bleeding Events in Interventional Pharmacology
This presentation by Franz Weidinger of the Medical Department Cardiology at the Hospital Rudolfstiftung in Vienna, Austria will discuss the relevance of bleeding as a clinical endpoint, the availability of potent antithrombotic therapy, and the increased risk of bleeding that comes with it. Weidinger will examine the new BARC definition of bleeding events and its impact on patient outcomes.
- Uploaded on | 0 Views
About Bleeding Risk Estimation and the New BARC Definition of Bleeding Events in Interventional Pharmacology
PowerPoint presentation about 'Bleeding Risk Estimation and the New BARC Definition of Bleeding Events in Interventional Pharmacology'. This presentation describes the topic on This presentation by Franz Weidinger of the Medical Department Cardiology at the Hospital Rudolfstiftung in Vienna, Austria will discuss the relevance of bleeding as a clinical endpoint, the availability of potent antithrombotic therapy, and the increased risk of bleeding that comes with it. Weidinger will examine the new BARC definition of bleeding events and its impact on patient outcomes.. The key topics included in this slideshow are bleeding risk, BARC definition, interventional pharmacology, clinical endpoint, antithrombotic therapy,. Download this presentation absolutely free.
1. Franz Weidinger 2. Medical Department (Cardiology) Hospital Rudolfstiftung Vienna, Austria SOLACI 12, Mexico City, Interventional Pharmacology 2, Thursday 15:15/16:45 2. Room Chapultepec Bleeding Risk Estimation and the New (BARC) Definition of Bleeding Events
2. Relevance of bleeding as a clinical endpoint Availability of potent antithrombotic therapy including ASA P2Y 12 inhibitors (clopidogrel, prasugrel, ticagrelor) heparin GP IIb/IIIa inhibitors direct thrombin inhibitors has led to a reduction in ischemic events but is associated with an increased risk of bleeding the increase in bleeding is associated with worse clinical outcome
3. All antithrombotic agents (except fondaparinux, bivalirudin) are All antithrombotic agents (except fondaparinux, bivalirudin) are associated with increased bleeding risk associated with increased bleeding risk Aspirin and heparin reduce death/ MI at 30 days in NSTE-ACS Aspirin and heparin reduce death/ MI at 30 days in NSTE-ACS
4. Hypothetical mechanisms linking bleeding and mortality Steg P G et al. Eur Heart J 2011;32:1854-1864
5. Steg P G et al. Eur Heart J 2011;32:1854-1864
6. Construction of bleeding definitions using different categories of data elements Rao & Mehran, Circulation 2012;125:1344-1346
7. Existing bleeding scores TIMI Laboratory-based (hemoglobin, hematocrit decrease) GUSTO Clinical (severity)-based GRACE Simplified laboratory and clinical CURE Major/ minor (combined clin. + lab) ACUITY Major (intracranial/-ocular, access-site, retroperit.), lab REPLACE-2 ISAR-REACT 3 PLATO STEEPLE CURRENT-OASIS Thrombolysis/ conservative PCI-based
8. Rationale for a new bleeding definition Increased importance of bleeding as prognostic factor Need for assessment of bleeding in RCTs and registries Lack of comparability Need for standardized definitions to avoid erroneous conclusions regarding safety of a given agent regarding superiority of one agent over another
9. BARC (Bleeding Academic Research Consortium) definitions, Mehran et al, Circulation 2011;123:2736-2747 Type 0 : no evidence of bleeding Type 1 : bleeding that is not actionable, without need for hospitalization or treatment (e.g. bruising, hematoma, nosebleeds, etc.) Type 2 : any clinically overt sign of hemorrhage that is actionable but does not meet criteria for type 3, 4 or 5. Must meet at least 1 of following criteria: Requires intervention Leads to hospitalization Prompts evaluation
10. BARC (Bleeding Academic Research Consortium) definitions, Mehran et al, Circulation 2011;123:2736-2747 Type 3 : clinical, laboratory, and/or imaging evidence of bleeding, with healthcare provider responses: BARC type 3a: any transfusion with overt bleeding overt bleeding plus hemoglobin drop 3 to <5 g/dL BARC type 3b: overt bleeding plus hemoglobin drop >5 g/dL Cardiac tamponade Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid) Bleeding requiring intravenous vasoactive drugs BARC type 3c: Intracranial hemorrhage, subcategories confirmed by autopsy, imaging or lumbar puncture Intraocular bleed compromising vision
11. BARC (Bleeding Academic Research Consortium) definitions, Mehran et al, Circulation 2011;123:2736-2747 Type 4 : Coronary Artery Bypass Graftrelated bleeding Perioperative intracranial bleeding within 48 hours Reoperation after closure of sternotomy for the purpose of controlling bleeding Transfusion of 5 U whole blood or packed red blood cells within a 48-hour period Chest tube output 2 L within a 24-hour period Notes: If a CABG-related bleed is not adjudicated as at least a type 3 severity event, it will be classified as not a bleeding event. If a bleeding event occurs with a clear temporal relationship to CABG (ie, within a 48-hour time frame) but does not meet type 4 severity criteria, it will be classified as not a bleeding event. Type 5: Fatal bleeding
12. Type 5 fatal bleeding Probable fatal bleeding (type 5a) bleeding that is clinically suspicious as the cause of death, but the bleeding is not directly observed and there is no autopsy or confirmatory imaging. Definite fatal bleeding (type 5b) bleeding that is directly observed (by either clinical specimen [blood, emesis, stool, etc] or imaging) or confirmed on autopsy BARC fatal bleeding is meant to capture deaths that are directly due to bleeding with no other cause. The time interval from the bleeding event to the death should be considered with respect to likely causality, but there is no specific time limit proposed.
13. Type 2 bleeding - further explanations Requires intervention: defined as a healthcare professional guided medical treatment or percutaneous intervention to stop or treat bleeding, including temporarily or permanently discontinuing a medication or study drug Examples include coiling, compression, use of reversal agents (Vit. K, protamine), local injections to reduce oozing, or a temporary/permanent cessation of antiplatelet, antithrombin, or fibrinolytic therapy
14. Type 2 bleeding - further explanations Leads to hospitalization or an increased level of care: defined as leading to or prolonging hospitalization or transfer to a hospital unit capable of providing a higher level of care Prompts evaluation: defined as leading to an unscheduled visit to a healthcare professional resulting in diagnostic testing (laboratory or imaging). Examples include, but are not limited to, hematocrit testing, hemoccult testing, endoscopy, colonoscopy, computed tomography scanning, or urinalysis.
15. Open questions regarding BARC Why 48-hour window for CABG-related bleeding? Why type 1 not actionable when patient may take action such as discontinuing medication (with potentially serious consequences such as ST)? Why consider intraocular bleed equivalent to intracranial bleed for BARC 3c? Type 1 bleed subject to misinterpretation by the patient Hicks et al (editorial), Circulation 2011;123:2664
16. Predictors of bleeding in acute coronary syndrome Steg P G et al. Eur Heart J 2011;32:1854-1864 Age, female sex, renal insufficiency, history of bleeding, use of invasive Age, female sex, renal insufficiency, history of bleeding, use of invasive procedures, lower body weight are powerful predictors of bleeding in ACS procedures, lower body weight are powerful predictors of bleeding in ACS
17. Validation of the BARC bleeding definitions in patients with CAD undergoing PCI (pooled analysis of 12,459 pts of 6 RCTs) Ndrepepa G et al., Circulation 2012;125:1424-1431 Comparison of bleeding definitions: BARC TIMI REPLACE-2 Bleeding confirmed as independent predictor of death All 3 definition criteria improved prediction Comparable predictivity of all 3 definitions with respect to 1-year mortality
18. Conclusion BARC is a new objective, hierarchically graded classification of bleeding (Mehran, Circulation [June 14] 2011:123:2736) BARC is based on consensus rather than data-driven Prospective validation is warranted across the spectrum of IHD across management strategies (conservative, invasive) in the context of all invasive procedures (PCI, CABG, endovascular, TAVI)
19. Conclusion (2) Final validation of BARC and proof of its utility depend on its use by all future RCTs as common safety endpoint unanimous assessment procedure (questionnaires) More important than using one or the other bleeding risk score is the agreement and commitment among clinical trialists to use the same score for comparability of data!
20. Thank you !